Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $562.3 million.

  • Ani Pharmaceuticals' Goodwill & Intangibles fell 1078.21% to $562.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.3 million, marking a year-over-year decrease of 1078.21%. This contributed to the annual value of $601.8 million for FY2024, which is 15368.8% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Goodwill & Intangibles stood at $562.3 million for Q3 2025, which was down 1078.21% from $580.9 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Goodwill & Intangibles peaked at $630.3 million during Q3 2024, and registered a low of $173.7 million during Q3 2021.
  • Its 5-year average for Goodwill & Intangibles is $401.6 million, with a median of $528.4 million in 2021.
  • In the last 5 years, Ani Pharmaceuticals' Goodwill & Intangibles soared by 20837.43% in 2022 and then tumbled by 5813.69% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Goodwill & Intangibles (Quarter) stood at $528.4 million in 2021, then tumbled by 47.04% to $279.9 million in 2022, then dropped by 15.23% to $237.2 million in 2023, then surged by 153.69% to $601.8 million in 2024, then fell by 6.57% to $562.3 million in 2025.
  • Its last three reported values are $562.3 million in Q3 2025, $580.9 million for Q2 2025, and $599.2 million during Q1 2025.